$1.92
6.98% today
NYSE, Oct 03, 03:53 pm CET
ISIN
US44486Q1031
Symbol
HUMA

Humacyte Stock price

$1.79
+0.28 18.54% 1M
+0.33 22.60% 6M
-3.26 64.55% YTD
-3.90 68.54% 1Y
-1.42 44.24% 3Y
-7.88 81.49% 5Y
-7.88 81.49% 10Y
-7.88 81.49% 20Y
NYSE, Closing price Thu, Oct 02 2025
+0.03 1.70%
ISIN
US44486Q1031
Symbol
HUMA
Industry

Key metrics

Basic
Market capitalization
$284.3m
Enterprise Value
$263.5m
Net debt
positive
Cash
$38.0m
Shares outstanding
156.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
346.7 | 74.5
EV/Sales
321.4 | 69.0
EV/FCF
negative
P/B
70.2
Financial Health
Equity Ratio
-38.2%
Return on Equity
282.9%
ROCE
-94.4%
ROIC
-118.2%
Debt/Equity
4.3
Financials (TTM | estimate)
Revenue
$820.0k | $3.8m
EBITDA
$-103.8m | $-60.5m
EBIT
$-111.1m | $-102.2m
Net Income
$-58.7m | $-48.8m
Free Cash Flow
$-105.9m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-4.3% | 43.4%
EBIT
-4.1% | 10.4%
Net Income
58.1% | 67.3%
Free Cash Flow
-28.7%
Margin (TTM | estimate)
Gross
56.0%
EBITDA
-12,693.4% | -1,584.2%
EBIT
-13,587.3%
Net
-7,178.6% | -1,278.1%
Free Cash Flow
-12,949.1%
More
EPS
$-0.4
FCF per Share
$-0.7
Short interest
24.8%
Employees
219
Rev per Employee
$0.0
Show more

Is Humacyte a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

Humacyte Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Humacyte forecast:

10x Buy
83%
2x Hold
17%

Analyst Opinions

12 Analysts have issued a Humacyte forecast:

Buy
83%
Hold
17%

Financial data from Humacyte

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
0.82 0.82
-
100%
- Direct Costs 0.36 0.36
-
44%
0.46 0.46
-
56%
- Selling and Administrative Expenses 31 31
33% 33%
3,741%
- Research and Development Expense 60 60
28% 28%
7,360%
-104 -104
4% 4%
-12,662%
- Depreciation and Amortization 7.31 7.31
1% 1%
891%
EBIT (Operating Income) EBIT -111 -111
4% 4%
-13,554%
Net Profit -59 -59
58% 58%
-7,161%

In millions USD.

Don't miss a Thing! We will send you all news about Humacyte directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Humacyte Stock News

Neutral
GlobeNewsWire
4 days ago
– Patent covers esophagus produced using Humacyte's proprietary bioengineered regenerative tissue platform, designed for implant in patients with damaged esophagus – – Patent provides coverage into 2041 for the composition of novel bioengineered esophagus – DURHAM, N.C., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developin...
Neutral
GlobeNewsWire
15 days ago
- Results were published in JACC: Basic to Translational Science - - Publication evaluated coronary tissue engineered vessel (CTEV) as a conduit for CABG in a nonhuman primate model - - All implanted CTEVs remained patent through six months, demonstrated adaptive remodeling, and recellularized with host coronary artery cells – - Humacyte plans to advance CTEV into first-in-human study in CABG -...
Neutral
GlobeNewsWire
18 days ago
- Results were published in the Journal of Vascular Surgery - - Publication described treatment of patients with Symvess who had hospital-acquired iatrogenic injuries or complications of vascular surgical procedures - - Patients treated with Symvess were observed to have high levels of patency, 100% limb salvage, and zero cases of conduit infection - DURHAM, N.C., Sept. 15, 2025 (GLOBE NEWSWIRE...
More Humacyte News

Company Profile

Humacyte, Inc. engages in the business of developing and manufacturing off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs, and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. The company was founded by Laura E. Niklason, Shannon Dahl, and Juliana L. Blum on October 13, 2004 and is headquartered in Durham, NC.

Head office United States
CEO Laura Niklason
Employees 219
Founded 2004
Website humacyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today